Pre-clinical murine studies addressing RANKL inhibition in both preventive and therapeutic settings have shown that targeting RANK-expressing cancer cells not only decreases BM tumor burden but also prevents BM onset [37,61]. Here, TNFSF11 is linked to cancer.